Navigation Links
Industry Professionals Get Schooled in Real-World Oncology Issues at NCCN Academy

NCCN announces open registration for a west coast session of NCCN Academy for Excellence & Leadership in Oncology(TM) School of Pharmaceutical & Biotech Business scheduled for July 9 - 10, 2009 in San Francisco. This new educational offering is designed to give pharmaceutical and biotech professionals the rare opportunity to view the oncology space and its current and future operational issues from the provider and payer perspective.

FORT WASHINGTON, Pa., June 8 /PRNewswire-USNewswire/ -- Industry professionals from pharmaceutical and biotech companies have the opportunity to become students for the day and improve their knowledge of real-world oncology issues at the NCCN Academy for Excellence & Leadership in Oncology(TM) School of Pharmaceutical & Biotech Business scheduled for July 9 - 10, 2009 in San Francisco.

The School of Pharmaceutical & Biotech Business is the first in the NCCN Academy for Excellence & Leadership in Oncology(TM) series of oncology certificate programs designed by the National Comprehensive Cancer Network (NCCN) to improve the working knowledge of key business, policy, coverage, clinical, reimbursement, informational, and operational issues in oncology and gather valuable insights for developing effective strategies for navigating the various constituencies in cancer care.

"With constant changes to both the clinical aspects and policy impacting the practice of oncology, clinicians are calling for business professionals to be well-versed in relevant information beyond the products they represent," says William T. McGivney, Ph.D., Chief Executive Officer, NCCN. "As an authoritative source in oncology care, NCCN is pleased to offer robust, educational programs through NCCN Academy that can help professionals integrate key advances and marketplace changes into their business operations and decisions."

The School of Pharmaceutical & Biotech Business program features an interactive curriculum that exposes participants to the current environment, trends, and controversies facing the oncology sector and discussion about how key stakeholders, including industry, can create mutually successful working relationships. The scope of the subject matter is far reaching and ranges from the science and business of oncology; to the future of oral chemotherapy and biologics; to frank discussions about cancer policy, coverage and reimbursement, and working effectively with key decision makers.

NCCN Academy offers an introductory curriculum as well as an advanced program; the July program will offer advanced learning for experienced professionals.

Recent reports show that physicians find considerable value in meeting with industry representatives whose knowledge goes beyond product information, making for a more substantive, credible discussion. The School of Pharmaceutical & Biotech Business provides a casual and open learning atmosphere to help professionals better understand the impact of information on data and decisions that influence the availability and use of drugs and biologics in cancer care.

Enrollment is currently open for the west coast session of NCCN Academy for Excellence & Leadership in Oncology(TM) School of Pharmaceutical & Biotech Business scheduled for July 9 - 10 in San Francisco, as well as a session in Chicago scheduled for October 14 - 15. Complete registration information and a syllabus is available at

Additional Schools within NCCN Academy for Excellence & Leadership in Oncology will include programs for cancer center administrators, clinical executive leaders, and oncology fellows in addition to pharmaceutical and biotech professionals.

About the National Comprehensive Cancer Network

The National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world's leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives.

The NCCN Member Institutions are: City of Hope Comprehensive Cancer Center, Los Angeles, CA; Dana-Farber/Brigham and Women's Cancer Center | Massachusetts General Hospital Cancer Center, Boston, MA; Duke Comprehensive Cancer Center, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Memorial Sloan-Kettering Cancer Center, New York, NY; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; The Ohio State University Comprehensive Cancer Center -- James Cancer Hospital and Solove Research Institute, Columbus, OH; Roswell Park Cancer Institute, Buffalo, NY; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO; St. Jude Children's Research Hospital/University of Tennessee Cancer Institute, Memphis, TN; Stanford Comprehensive Cancer Center, Stanford, CA; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; UNMC Eppley Cancer Center at The Nebraska Medical Center, Omaha, NE; The University of Texas M. D. Anderson Cancer Center, Houston, TX; and Vanderbilt-Ingram Cancer Center, Nashville, TN.

For more information on NCCN, please visit

SOURCE National Comprehensive Cancer Network
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cynvec to Present at the 11th Annual Shanghai International Forum on Biotechnology and Pharmaceutical Industry
2. Microsoft Signs Agreement With Merck & Co. Inc. to Acquire Assets of Rosetta Biosoftware, Strengthening Position in Life Sciences Industry
3. Microtest Laboratories is an Industry Leader in ICH Stability Testing
4. MichBio Leader Cites New Senate Biosciences Task Force and House Subcommittee as Evidence of States Growing Awareness of Industrys Economic Importance
5. Sugarcane Ethanol Industry Eager to Implement U.S. Renewable Fuel Standard
6. Industry Expert Reveals Cutting Edge Biotechnology Science for Nutraceutical and Functional Food Applications
7. Opus Environmental Introduces Innovative Food Waste Elimination Equipment to U.S. Food Industry
8. Key Industry-Relevant Development to be Announced at MichBios 2009 Annual Meeting on May 6
9. SAFC Hitech & Air Water Inc. Extend High-End Materials Research Services Collaboration to Support Japan Chip Industry
10. Encorium Named as Finalist for the Second Annual Vaccine Industry Excellence Award
11. Isilon Hosts Industry Leaders Panel on the Future of Life Sciences and IT at Bio-IT World 2009
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... Pittcon is ... 2,000 technical presentations offered in symposia, oral sessions, workshops, awards, and posters. ... wide range of applications such as, but not limited to, biotechnology, biomedical, drug ...
(Date:11/25/2015)... --> ... 2020 report analyzes that automating biobanking workflow will ... long-term samples, minimizing manual errors, improving the workflow ... errors such as mislabeling or inaccurate sample barcoding ... a vital role in blood fractionation, DNA extraction, ...
(Date:11/25/2015)... HOLLISTON, Mass. , Nov. 25, 2015 /PRNewswire/ ... ), a biotechnology company developing bioengineered organ implants for ... will present at the LD Micro "Main Event" ... p.m. PT. The presentation will be webcast live and ... will also be available at the conference for one-on-one ...
(Date:11/25/2015)... , Nov. 25, 2015 Orexigen® Therapeutics, Inc. ... participate in a fireside chat discussion at the Piper ... York . The discussion is scheduled for Wednesday, ... .  A replay will be available for ... Stilwell  , Julie NormartVP, Corporate Communications and Business ...
Breaking Biology Technology:
(Date:11/9/2015)... Nov. 9, 2015  Synaptics Inc. (NASDAQ: SYNA ... announced broader entry into the automotive market with a ... the pace of consumer electronics human interface innovation. Synaptics, ... ideal for the automotive industry and will be implemented ... Europe , Japan , ...
(Date:11/2/2015)... , Nov. 2, 2015  SRI International has been ... provide preclinical development services to the National Cancer Institute ... will provide scientific expertise, modern testing and support facilities, ... preclinical pharmacology and toxicology studies to evaluate potential cancer ... The PREVENT Cancer Drug Development Program is an ...
(Date:10/29/2015)... Oct. 29, 2015  The J. Craig Venter Institute ... "DNA Synthesis and Biosecurity: Lessons Learned and Options for ... Health and Human Services guidance for synthetic biology providers ... --> --> Synthetic ... the potential to pose unique biosecurity threats. It now ...
Breaking Biology News(10 mins):